Analysis reveals 61% of inflammatory bowel disease-related colorectal cancers were post-colonoscopy, often due to delays in surveillance and missed lesions in areas of inflammation. Proactive strategies are needed to reduce endoscopic burden and improve surveillance adherence, as traditional methods show limitations in detecting aggressive cancer evolution. Molecular biomarkers may enhance risk assessment in future clinical practice.
Multicenter Study by Kabir M, Thomas-Gibson S (…) Wilson A et 11 al. in J Crohns Colitis
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.